AUPH
Aurinia Pharmaceuticals Inc.
AUPH's fundamentals are strong and it looks cheap: trading at 7.1x earnings, less than half its usual 26x. Analysts expect earnings to hold roughly steady.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
AUPH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Strong |
AUPH's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
AUPH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.1x | $16.18 | -0.2% |
| Current | 7.1x | $16.21 | — |
| Forward | 19x | $16.21 | — |
| Fair | 26x | $59.75 | +269% |
| Expensive | 31x | $70.12 | +333% |
Historical ranges are pointers, not guarantees.
AUPH's PE is in its cheap range at 7.1x. On analysts' estimates for next year's earnings, today's price would be 19x, in its fair range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
AUPH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Stable | |
| Growth | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect AUPH's revenue to grow, but its profitability to weaken.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
AUPH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.83 | -64% |
| Q3 2026 | $2.29 | +309% |
| Q2 2026 | $2.29 | +433% |
| Q1 2026 | $2.17 | +675% |
| Q4 2025 | $2.08 | +4060% |
| Q3 2025 | $0.56 | +$0.71 |
| Q2 2025 | $0.43 | +$0.77 |
| Q1 2025 | $0.28 | +$0.71 |
| Q4 2024 | $0.05 | +$0.59 |
AUPH has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
AUPH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $83.7M | +14% |
| Q2 2026 | $83.2M | +19% |
| Q1 2026 | $77.7M | +24% |
| Q4 2025 | $77.1M | +29% |
| Q3 2025 | $73.5M | +8.4% |
| Q2 2025 | $70M | +22% |
| Q1 2025 | $62.5M | +24% |
| Q4 2024 | $59.9M | +33% |
AUPH's revenue has grown year over year for 12 quarters in a row: $84M last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 42% | +1.8 points |
| Q2 2026 | 56% | +27 points |
| Q1 2026 | 53% | +18 points |
| Q4 2025 | 43% | +46 points |
| Q3 2025 | 40% | +23 points |
| Q2 2025 | 29% | +31 points |
| Q1 2025 | 35% | +61 points |
| Q4 2024 | -2.8% | +63 points |
AUPH has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over AUPH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
AUPH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $46.4M | +4.3% |
| Q2 2026 | $52.6M | +19% |
| Q1 2026 | $32.6M | +2405% |
| Q4 2025 | $45.7M | +52% |
| Q3 2025 | $44.4M | +161% |
| Q2 2025 | $44.2M | +179% |
| Q1 2025 | $1.3M | +$19.9M |
| Q4 2024 | $30.1M | +110% |
AUPH has the edge over HIMS on cash flow, with more consistent year-over-year improvement.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
AUPH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1.6M shares |
| 1 year | -0.6% | -835K shares |
| 3 years | -5.4% | -7.7M shares |
| 5 years | +5.2% | +6.7M shares |
| Available history | +38% | +37.2M shares |
AUPH has 135M diluted shares, down 0.6% from a year ago, with $75M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $38.7M |
| Q1 2026 | $36.2M |
| Q4 2025 | — |
| Q3 2025 | $8.7M |
| Q2 2025 | $42.6M |
| Q1 2025 | $46.9M |
| Q4 2024 | $21.8M |
AUPH spent $75M buying back its own shares over the past year, down 38% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over AUPH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
AUPH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -1.1x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -0.6x | Net Cash |
| Q3 2025 | -1.0x | Net Cash |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
AUPH has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
AUPH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.9 | Neutral |
| Stochastic | 57.0 | Neutral |
AUPH's weekly RSI is 52 (neutral) and its Stochastic is 57 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
AUPH PE vs Healthcare Sector
| Metric | AUPH | Sector median | Relative |
|---|---|---|---|
| PE | 7.1x | 26x | 73% below |
| PE % | 18 | 29 | 11 pts below |
AUPH is trading at 7.1x earnings, a 73% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
AUPH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.5 | 1.5% below |
| 20 week MA | $16.1 | 0.5% above |
| 50 week MA | $15.6 | 3.9% above |
| 100 week MA | $12.7 | 27% above |
| 200 week MA | $10.3 | 57% above |
AUPH has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
AUPH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.4 | $14.2 | -34% |
| 2021 | $14.2 | $23.1 | +63% |
| 2022 | $23.1 | $4.53 | -80% |
| 2023 | $4.53 | $8.99 | +98% |
| 2024 | $8.99 | $9.20 | +2.3% |
| 2025 | $9.20 | $16.3 | +77% |
| 2026 YTD | $16.3 | $16.2 | -0.2% |
AUPH has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.